Adams Respiratory Therapeutics Inc
Adams Respiratory Therapeutics — Q2 FY2007 Earnings Presentation
28 slides from Adams Respiratory Therapeutics's earnings presentation, Feb 7, 2007

Slide 1: Fiscal 2007 Second Quarter Earnings Results
Fiscal 2007 Second Quarter Earnings Results February 7, 2007

Slide 2: Safe Harbor
Safe Harbor This presentation contains certain "forward-looking" statements. These statements are based on the current estimates and assumptions of the management of Adams Respiratory Therapeutics, Inc. (or "Adams") as of the date of this presentation and are naturally subject to uncertainty and cha

Slide 3: Strong Growth in Revenues
12- Months Ended 6- Months Ended Strong Growth in Revenues (in millions) 6/03 12/05 6/04 6/05 YoY Growth 82% CAGR '03-'06 158 % 12/06 6/06 $239.1 $110.3 $14.0 $61.3 $160.2 $200.7 $0.0 $50.0 $100.0 $150.0 $200.0 $250.0 $300.0

Slide 4: Strong Q2 Financial Performance
Strong Q2 Financial Performance Net sales increased 75% to $110.6 MM Pretax income increased 12% to $19.4 MM* Net income increased 17% to $12.5 MM* Income per diluted share increased 17% to $0.34* *Includes a non-cash, pretax charge of $2.7 MM, or $0.04 per diluted share, related to the AlleRx royal

Slide 5: Fiscal Second Quarter Net Sales by Major Product
2007 Fiscal Second Quarter Net Sales by Major Product $39,224 $30,646 $9,130 $18,475 Acquired 6/06 $12,571 Launched 8/06 ($ in thousands) Accelerating Growth Rate Total Net Sales = $110.6 MM +75% vs. Q2 FY06

Slide 6: Mucinex Brand a Category Leader
Mucinex(r) Brand a Category Leader Mucinex(r) Brand a Category Leader SE 20's # 3 # 13 DM 20's # 6 # 22 SE 40's # 7 All OTC SKUs All Items Top 500 UPC Dollar Ranking at Drug Outlets (2) Higher ranking SKUs: 6 cigarettes 4 beverages 2 OTC products Source: Information Resources, Inc. (IRI) Brand Ranki

Slide 7: Erdosteine
Erdosteine In-licensed mucoregulator compound with a unique profile Improvements in mucociliary clearance, mucus volume, flow characteristics and cough(1) Approved in more than 30 foreign markets; approx. 24 million patient exposures Phase IIb clinical program completed Dec. 2006 400 patients with c

Slide 8: Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant
Adams Seeks FDA Approval for its First Rx - A New Cough Suppressant NDA submitted Dec. 2006 600/1200 mg guaifenesin (GGE) combinations Approx. 24 MM cough Rx's/year(1) Two other GGE products in development (1) Source: IMS Health NPA reports - MAT 2/06; MAT 3/06.

Slide 9: Accelerated Development and Diversification
Fiscal 2006 Fiscal 2007 Accelerated Development and Diversification Fiscal 2008 Expect to double existing portfolio

Slide 10: Robert D. Casale
ADAMS RESPIRATORY THERAPEUTICS™ a Robert D. Casale [eeje)

Slide 11: FAN Data Tracks Strength of Season
FAN Data Tracks Strength of Season Source: Surveillance Data Inc. FAN U.S. National Report for the period ended 2/2/07. Affected Population Season-to-date: -1.8% (VYA)

Slide 12: FAN Data Tracks Symptoms
FAN Data Tracks Symptoms FAN Data Tracks Symptoms FAN Data Tracks Symptoms FAN Data Tracks Symptoms FAN Data Tracks Symptoms Source: Surveillance Data Inc. FAN U.S. National Report for the period ended 2/2/07. - -6.4% - -4.1% - -5.7% - -5.0% Cough Sore Throat Fever Chest Congestion, Fever, Body Ache

Slide 13: Solid Retail Market Performance
Solid Retail Market Performance IRI data: 4-Weeks ended Dec. 31, 2006 Total retail dollar sales growth in the C/C/A/S category: +20% vs. prior 4 week period (VPP) +3% vs. year ago 4 week period (VYA) Total Mucinex(r) retail dollar sales outpace the category +23% VPP +48% VYA Total Mucinex(r) achieve

Slide 14: Delsym Dollar Sales Reach New High
Source: IRI data through 12/31/06. Source: IRI data through 12/31/06. Millions Adams Acquired Delsym(r) Professional Promotion Began Consumer Advertising Began Delsym(r) Dollar Sales Reach New High +38% VPP +48% VYA

Slide 15: Adams Products Ranking in the Top
Adams Products Ranking in the Top 10 Source: IRI Brand Ranking Report for the 4-week period ended 12/31/06 in the c/c/a/s category. F/D/MX Rank Brand Sales 1 Airborne $16,772,848 2 Mucinex SE $12,488,018 3 Vicks Nyquil $12,460,688 4 Mucinex DM $11,685,348 5 Sudafed $11,588,213 6 Claritin D $9,411,25

Slide 16: Mucinex A Category Leader Among Key Competitors
Mucinex(r) A Category Leader: No. 2 Brand Among Key Competitors Source: IRI, U.S. F/D/Mx, c/c/a/s market for the 4-week periods ended 12/25/05 and 12/3106. Source: IRI, U.S. F/D/Mx, c/c/a/s market for the 4-week periods ended 12/25/05 and 12/3106. (r) (r)

Slide 17: Mucinex Total Brand Awareness
Mucinex(r) Total Brand Awareness Current Season vs. Last Season Source: Company sponsored research. Source: Company sponsored research.

Slide 18: Adams Gaining Category Strength
Source: IRI data for the c/c/a/s market for the 4 weeks ended 12/31/06. Adams Gaining Category Strength 3.7 3.5 1.2 0.7 0.5 2.3 Mucinex(r) Mucinex(r) DM Mucinex(r) D Mucinex(r) Children's Liquids Mucinex(r) Children's Mini-Melts Delsym(r) Dollar Share of C/C/A/S Category by Major Product +5.2 points

Slide 19: Dollar Market Share for Children's Mucinex and Delsym Continues to Accelerate
Dollar Market Share for Children's Mucinex(r) and Delsym(r) Continues to Accelerate Source: IRI data for the pediatric and cough syrup segments of the c/c/a/s category for the periods ended 12/31/06. +6.3 pts VYA +4.8 pts VYA +1.2 pts VYA

Slide 20: Michael J. Valentino, President and CEO
Michael J. Valentino President and CEO

Slide 21: Mucinex Product Launches and Rx Market History
Consumer Advertising February 2006 Competing Product Removal? Competing Product Removal? FDA Exclusivity Decision Pending Consumer Advertising November 2004 Competing Products Removed December 2003 Launched July 2002 Approved July 2002 $125 MM Rx market $20 MM Rx market Consumer Advertising November

Slide 22: Relevant OTC Categories and Generic Markets
Relevant OTC Categories P/L Sales (1) Gastrointestinal 25% Analgesics 24% Cold/allergy/sinus 22% (1) Percent of total category sales as per IRI data for the twelve months ended Nov. 5, 2006. Dramatic Differences Between Rx and OTC Generic Markets Typical OTC generic encroachment 20-25% Typical Rx ge

Slide 23: Current Situation
Current Situation 400 mg immediate-release generics available for the past 18 months The Mucinex(r) franchise has continued to experience explosive growth in terms of market share and revenue growth Current dollar share estimated at 12% - 15% of the mucus-based category We believe a future extended-

Slide 24: David P. Becker, CFO, CAO, and Treasurer
David P. Becker CFO, CAO, and Treasurer

Slide 25: Top-Line Diversification Continues
Top-Line Diversification Continues Top-Line Diversification Continues $16.3 MM or ~34% $31.0 MM or ~66% Net Sales growth = $47.3 million

Slide 26: Production Capacity Increasing
Production Capacity Increasing Jan. 2006 Run Rate Q3 FY 06 Run Rate Q1 FY 07 Run Rate Current Run Rate $450 MM $340 - $350 MM $100 MM $200 MM $300 MM $400 MM $500 MM $450 MM+ Source: Internal estimates. Liquids and granules $100 MM+ $600 MM $500 MM Completed multiple capital projects and process imp

Slide 27: Income Statement Overview
Income Statement Overview $110.6 $63.2 $239.1 $160.2 $61.3 Net Sales 75.9% 78.0% 79.4% 80.6% 80.5% Gross Margin % $19.4 17.6% $17.4 27.5% $76.2 32% $44.4 28% $19.7 32% Pretax Income % of Net Sales $12.5 $10.7 $46.4 $27.0 $35.8 Net Income 2006 2005 2006 2005 2004 Three months ended Dec. 31, Years end

Slide 28: Fiscal 2007 Second Quarter Earnings Results
Fiscal 2007 Second Quarter Earnings Results February 7, 2007
Source: SEC EDGAR · 8-K filed Feb 7, 2007
More decks from Adams Respiratory Therapeutics Inc
Q1 FY2008 Earnings Presentation12 slides · Nov 8, 2007
Q3 FY2007 Earnings Presentation21 slides · May 10, 2007
Technical Presentation (April 2007)25 slides · Apr 4, 2007
Investor Presentation (April 2007)10 slides · Apr 4, 2007
Investor Presentation (April 2007)60 slides · Apr 4, 2007
Merrill Lynch 18th Annual Global Pharmaceutical, Biotechnology and Medical Device Conferen (February 2007)21 slides · Feb 8, 2007